| Literature DB >> 28968287 |
Florian Ettl1, Ingrid A M Magnet1, Wolfgang Weihs1, Alexandra-Maria Warenits1, Daniel Grassmann1, Michael Wagner1, Ursula Teubenbacher2, Sandra Högler2, Fritz Sterz1, Andreas Janata1.
Abstract
PURPOSE: The aim of the study was to establish a ventricular fibrillation (VF) cardiac arrest (CA) resuscitation model with consistent neurologic and neuropathologic damage as potential therapeutic target.Entities:
Mesh:
Year: 2018 PMID: 28968287 PMCID: PMC6039375 DOI: 10.1097/SHK.0000000000001004
Source DB: PubMed Journal: Shock ISSN: 1073-2322 Impact factor: 3.454
Fig. 1Study design and experimental setup.
Fig. 2Timelines of experimental protocols.
Restoration of spontaneous circulation (ROSC) and survival till endpoint on day 14
| Protocol | Cardiac arrest | 6 min | 8 min | |||
| “Basic life support” | 6 min | 2 min | 2 min | |||
| Adrenaline | No | Yes | No | Yes | Yes | |
| Outcome | No ROSC | •••• | ••• | ••••• | •• | •• |
| ROSC | • | •• | •••••••• | ••••••••• | ||
| Survival | •• | ••••••• | •••••• | |||
Each dot represents one rat.
Outcome in terms of final overall performance categories (OPC 1: best, 5: worst) and neurologic deficit scores (NDS 0%–100%, mean ± SD) of phase 2 experiments at day 1 and day 14 after return of spontaneous circulation (P < 0.05)
| Cardiac arrest | |||||
| Sham | 6 min | 8 min | 6 min | 8 min | |
| Advanced life support and adrenaline | |||||
| Day 1 | Day 14 | ||||
| OPC 1 | •••• | •••••• | • | ••••••• | ••••• |
| OPC 2 | • | ••••• | • | ||
| OPC 3 | |||||
| OPC 4 | |||||
| OPC 5 | |||||
| NDS | 0.25 ± 0.5 | 3.83 ± 3.19 | 12.83 ± 4.49 | 0 ± 0 | 0.83 ± 2.04 |
Each dot represents one rat.
Physiologic baseline values and resuscitation variables of phase 2 experiments without significant differences between groups
| Cardiac arrest | |||
| 6 min (n = 7) | 8 min (n = 6) | ||
| Sham (n = 4) | Advanced life support and adrenaline | ||
| Weight (g) | 376 ± 11 | 366 ± 17 | 350 ± 16 |
| Surgery time (min) | 99.3 ± 46.7 | 78.6 ± 11.8 | 83.7 ± 11.9 |
| Heartrate (/min) | 366 ± 62 | 383 ± 30 | 375 ± 25 |
| Temperature (°C) | 36.9 ± 0.1 | 37.1 ± 0.1 | 37.1 ± 0.1 |
| MAP (mmHg) | 98 ± 22 | 110 ± 10 | 114 ± 12 |
| pH | 7.42 ± 0.02 | 7.41 ± 0.04 | 7.39 ± 0.02 |
| paCO2 (mmHg) | 40.9 ± 3.2 | 40.1 ± 6.5 | 40.9 ± 3.8 |
| paO2 (mmHg) | 136 ± 31 | 133 ± 34 | 104 ± 10 |
| Hb (g/dL) | 14.1 ± 0.5 | 14.4 ± 1.2 | 14.2 ± 1.1 |
| K (mmol/L) | 4.2 ± 0.7 | 4.2 ± 0.6 | 4.4 ± 0.5 |
| Glucose (mg/dL) | 181 ± 31 | 183 ± 42 | 162 ± 20 |
| Lactate (mmol/L) | 1.8 ± 0.3 | 1.4 ± 0.6 | 1.1 ± 0.1 |
| CPR time (min) | 2.6 ± 1.0 | 2.7 ± 1.0 | |
| Defibrillations (n) | 1.7 ± 1.0 | 2.3 ± 1.0 | |
| Epinephrine (mcg) | 45.7 ± 9.8 | 46.7 ± 10.3 | |
CPR, cardiopulmonary resuscitation; Hb, haemoglobin; K, potassium; MAP, mean arterial pressure; paCO2, arterial carbon dioxide partial pressure; paO2, arterial oxygen partial pressure.
Data are presented as mean ± SD.
Arterial blood gas analyses of phase 2 experiments taken (a) 5 min and (b) 15 min after ROSC
| (a) | ||||
| Cardiac arrest | ||||
| Sham (n = 4) | 6 min (n = 7) | 8 min (n = 6) | ||
| Advanced life support and adrenaline | ||||
| pH | 7.42 ± 0.24 | 7.09 ± 0.05 | 7.03 ± 0.06 | 0.104 |
| paCO2 (mmHg) | 40 ± 3 | 53 ± 8 | 54 ± 10 | 0.861 |
| paO2 (mmHg) | 130 ± 20 | 265 ± 58 | 291 ± 89 | 0.546 |
| Hb (g/dL) | 14 ± 0.2 | 15 ± 1 | 15 ± 1 | 0.930 |
| K (mmol/L) | 4.2 ± 0.4 | |||
| Glucose (mg/dL) | 168 ± 21 | 334 ± 26 | 346 ± 42 | 0.544 |
| Lactate (mmol/L) | 1.4 ± 0.2 | |||
Hb, haemoglobin; K, potassium; paCO2, arterial carbon dioxide partial pressure; paO2, arterial oxygen partial pressure.
Significant differences between the two cardiac arrest groups and corresponding P values are marked italic. Data are presented as mean ± standard deviation.
Fig. 3Representative sections of the hippocampal CA 1 region after 0, 6, and 8 min of cardiac arrest (CA).
Neuropathologic damage of phase 2 experiments at 14 days after cardiac arrest
| Cardiac arrest | |||
| Sham (n = 4) | 6 min (n = 7) | 8 min (n = 6) | |
| Advanced life support and adrenaline | |||
| Haematoxylin and eosin (counts of viable neurons) | 58.75 ± 6.08 | 27.86 ± 14.70 | 16.67 ± 4.31 |
| Fluoro-Jade (counts of dying neurons) | 0.00 ± 0.00 | 45.14 ± 19.23 | 62.67 ± 9.14 |
| Iba-1 immunostaining (semiquantitative–microglial activation) | 0 (0–0) | 3 (3–3) | 3 (3–4) |
Normally distributed values: mean ± SD; not normally distributed values: median (25–75th percentile).